- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
AntriaBio Announces First Patient Dosed in Clinical Study
AntriaBio announced the dosing of the first patient in their Phase 1 first-in-human clinical trial of its lead product candidate, AB101.
AntriaBio (OTCQB:ANTB) announced the dosing of the first patient in their Phase 1 first-in-human clinical trial of its lead product candidate, AB101.
As quoted in the press release:
“The successful filing of the IND followed by initiation of the first-in-human clinical trial for AB101 are significant milestones for our Company as these events validate our robust preclinical results and bring us to the doorstep of being able to demonstrate clinical proof-of-concept for AB101 as a once-weekly insulin,” stated Brian Roberts, M.D., Vice President of Clinical Development at AntriaBio. “Based on animal data, AB101 has the potential to improve overall glycemic control in patients with diabetes while offering a more convenient injection regimen compared to currently available basal insulins. The availability of such a therapy could optimize initiation and adherence to insulin and provide an important treatment option for patients and providers at a time when diabetes continues to increase to historic proportions.”
The Phase 1 clinical trial is a first-in-human single ascending dose study to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of AB101 in patients with type 1 diabetes mellitus.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.